Biointelligent Technology Systems SL
7
2
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
THERAVEX Tissue Care Spray Plus for the Management of Cutaneous Wounds, Burns, and Chronic Ulcers
Role: lead
Enhanced Early Soft-Tissue Healing With THERAVEX Technology
Role: lead
THERAVEX® REGENERA Tissue Care Plus for Hair Regeneration and Follicular Microenvironment Modulation
Role: lead
Effect of a Bioactive Mineral-Ionic Mouthrinse on Periodontal Soft Tissue Healing
Role: lead
Theravex® for Burning Mouth Syndrome
Role: lead
Theravex Oral and Theravex Tissue Care Plus in the Healing Process of Mucogingival Surgery
Role: collaborator
Bone Bioactive Liquid Efficiency in Improving Dental Implant Osteointegration Oral Soft Tissue Hellingand Oral Surgery
Role: lead
All 7 trials loaded